Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)

1.73 -0.1 (-5.464%)

IEX Real-Time Price

February 23, 2018 EST.

NYSE American : Healthcare

Prev Close 1.83

Price Open 1.73

Volume: 54,987

Avg Volume: 243,837

Market Cap: 28.29M

P/E Ratio -4.55

52 Wk Range 1.24-2.75



CANF Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-01-31
16.35M
691,907
2.00
4.23%

2018-01-12
16.35M
217,077
1.17
1.33%

2017-12-29
16.35M
45,202
0.59
0.28%

2017-12-15
16.35M
29,295
0.95
0.18%




CANF Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-03-30
Q4 2017
N/A
-0.14 (2)
0.00
0.00

2017-11-27
Q3 2017
N/A
-0.13 (2)
-0.04
0.09

2017-09-01
Q2 2017
N/A
-0.13 (2)
-0.12
0.01

2017-05-30
Q1 2017
N/A
-0.09 (1)
-0.08
0.01

News

Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson (2018-02-12 07:00 Business Wire)

Pre-clinical studies show Namodenosons mechanism of action in inhibiting inflammation and fibrosis in NASH models Can-Fite initiated lately patient enrollment for Phase II NAFLD/NASH Study with Namodenoson Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), …

 

Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf (2018-02-01 09:36 SeekingAlpha)

Does Can-Fite Biopharma ( CANF ) really want investors to take it seriously? Then stop the paid ad madness. The Israel-based company has been focused for the past two decades on trying to advance its experimental treatment for psoriasis and arthritis. But the biotech acts like the real foc…

 

Can-Fite Biopharma: Recent Positive Newsflow Not Reflected In Share Price (2018-01-26 08:23 SeekingAlpha)

Can-Fite Biopharma ( CANF ) is an Israel-based biopharmaceutical company, with a late-stage pipeline. The companys lead product candidate piclidenoson is currently in Phase 3 trial in two indications (rheumatoid arthritis or RA and moderate-to-severe plaque psoriasis). It has a second …

 

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results (2018-01-25 14:10 SeekingAlpha)

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss Synergy Pharmaceuticals ( SGYP ), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This…

 

Midday Gainers / Losers (1/25/2018) (2018-01-25 12:41 SeekingAlpha)

Gainers: LTBR +53% . KTEC +50% . MNKD +36% . OGEN +35% . OASM +32% . IOVA +27% . CANF +20% . EMAN +19% . LYTS +17% . TAL +17% . More news on: Lightbridge Corp, Key Technology, Inc., MannKind Corporation, Stocks on the move, Read more …

 

Your Daily Pharma Scoop: AbbVie Highlights Pipeline, Novavax Surges, Lipocine Flops At Ad Com (2018-01-12 09:47 SeekingAlpha)

Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss one of the most promising major biopharma companies, AbbVie ( ABBV ). At the ongoing JP Morgan Healthcare Conference, ABBV CEO Rick Gonzalez gave an overview of the pipeline and financials. The companys pipeline i…

 


Statistics

Shares Outstanding: 16.35M

Top 15 Institution Percent: 5.40

Price To Sales: 40.50

Price To Book: 8.59

Revenue: 740259

Gross Profit: N/A

Cash: 29.80M

Debt: N/A

Return On Assets: -55.97

Return On Equity: -123.37

Profit Margin: N/A

Price History

Beta: 1.94

50-day Moving Avg: 1.84

200-day Moving Avg: 1.72

YTD Change: 7.79

5-day Change: -15.61

1-month Change: -4.42

3-month Change: 20.98

6-month Change: 6.79

1-year Change: -8.47

Revenue Per Share: 0.00

Revenue Per Employee: 105751.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Exchange: NYSE American

Industry: Biotechnology

Sector: Healthcare

Website: http://www.canfite.com

Can Fite Biofarma Ltd is a clinical stage biopharmaceutical company. It develops orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases.